Loading...
Corteva Inc (CTVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts like strong EBITDA growth and upcoming spin-offs, the risks associated with the separation and mixed analyst sentiment make it prudent to hold off on buying right now. The technical indicators are neutral, and the options data suggests limited bullish sentiment. Additionally, the company's recent financial performance shows declining revenue, which raises concerns for long-term growth.
The technical indicators are mixed. The MACD is negative and expanding, suggesting bearish momentum. RSI is neutral at 54.849, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 74.11, with key resistance at 75.944 and support at 72.276.

Upcoming spin-off of the Seed and Crop Chemicals business, which could unlock value.
Strong EBITDA growth and resolution of litigation with Bayer.
Analysts like Wells Fargo, Goldman Sachs, and RBC Capital have raised price targets, citing positive developments.
UBS and JPMorgan downgraded the stock to Neutral, citing valuation concerns and risks associated with the spin-off.
Revenue declined by 1.71% YoY in Q4 2025, and the company posted a net loss.
The stock is facing selling pressure, as indicated by recent news and technical analysis.
In Q4 2025, revenue dropped by 1.71% YoY to $3.91 billion. However, net income improved significantly, up 1246.34% YoY, though it remains negative at -$552 million. EPS also improved to -0.82, up 1266.67% YoY. Gross margin increased to 38.29%, up 15.58% YoY.
Analyst sentiment is mixed. While some firms like Goldman Sachs and RBC Capital are bullish with price targets as high as $89, others like UBS and JPMorgan downgraded the stock to Neutral, citing valuation concerns and risks associated with the spin-off. The average price target is around $80, suggesting limited upside from the current price of $74.27.